[go: up one dir, main page]

ATE326481T1 - Veränderte tnfalpha-moleküle, dns, welche für derartige veränderte tnfalpha-moleküle kodiert und impfstoffe, die derartige veränderte tnfalpha-moleküle und dns enthalten - Google Patents

Veränderte tnfalpha-moleküle, dns, welche für derartige veränderte tnfalpha-moleküle kodiert und impfstoffe, die derartige veränderte tnfalpha-moleküle und dns enthalten

Info

Publication number
ATE326481T1
ATE326481T1 AT98916866T AT98916866T ATE326481T1 AT E326481 T1 ATE326481 T1 AT E326481T1 AT 98916866 T AT98916866 T AT 98916866T AT 98916866 T AT98916866 T AT 98916866T AT E326481 T1 ATE326481 T1 AT E326481T1
Authority
AT
Austria
Prior art keywords
tnfalpha
altered
molecules
dna
vaccines containing
Prior art date
Application number
AT98916866T
Other languages
English (en)
Inventor
Martin Roland Jensen
Soren Mouritsen
Henrik Elsner
Iben Dalum
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Application granted granted Critical
Publication of ATE326481T1 publication Critical patent/ATE326481T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98916866T 1997-04-15 1998-04-15 Veränderte tnfalpha-moleküle, dns, welche für derartige veränderte tnfalpha-moleküle kodiert und impfstoffe, die derartige veränderte tnfalpha-moleküle und dns enthalten ATE326481T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK41897 1997-04-15
US4418797P 1997-04-24 1997-04-24

Publications (1)

Publication Number Publication Date
ATE326481T1 true ATE326481T1 (de) 2006-06-15

Family

ID=8093298

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98916866T ATE326481T1 (de) 1997-04-15 1998-04-15 Veränderte tnfalpha-moleküle, dns, welche für derartige veränderte tnfalpha-moleküle kodiert und impfstoffe, die derartige veränderte tnfalpha-moleküle und dns enthalten

Country Status (30)

Country Link
US (1) US7118750B1 (de)
EP (1) EP0975668B1 (de)
JP (1) JP2001521386A (de)
KR (1) KR100522289B1 (de)
CN (1) CN1178955C (de)
AR (1) AR012427A1 (de)
AT (1) ATE326481T1 (de)
AU (1) AU743400B2 (de)
BR (1) BR9811462A (de)
CA (1) CA2289476A1 (de)
CZ (1) CZ9903657A3 (de)
DE (1) DE69834556T2 (de)
DK (1) DK0975668T3 (de)
EE (1) EE9900461A (de)
ES (1) ES2264569T3 (de)
HK (1) HK1022918A1 (de)
HR (1) HRP980203B1 (de)
HU (1) HUP0001930A3 (de)
IL (1) IL132281A0 (de)
NO (1) NO995002L (de)
NZ (1) NZ337955A (de)
PL (1) PL194221B1 (de)
RU (1) RU2241715C2 (de)
SI (1) SI0975668T1 (de)
SK (1) SK285639B6 (de)
TR (1) TR199902562T2 (de)
TW (1) TW510921B (de)
UA (1) UA72440C2 (de)
WO (1) WO1998046642A1 (de)
ZA (1) ZA983148B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
JP2002538170A (ja) * 1999-03-02 2002-11-12 セントコール， インコーポレイテッド 喘息の治療における抗−ＴＮＦα抗体
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
WO2001005820A2 (en) 1999-07-20 2001-01-25 Pharmexa A/S Method for down-regulating gdf-8 activity
JP2003535905A (ja) * 2000-06-21 2003-12-02 フェリング ベスローテン フェンノートシャップ 可溶化されたタンパク質ワクチン
WO2003075951A2 (en) * 2002-03-11 2003-09-18 Pharmexa A/S Novel application of vaccination against tnf-alpha
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
US7892558B2 (en) * 2004-02-27 2011-02-22 Vaxconsulting Isolated TNF-alpha peptide and pharmaceutical composition thereof
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
CA2608728A1 (en) 2005-05-16 2006-11-23 Abbott Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
BRPI0817705A2 (pt) * 2007-09-25 2015-03-31 Intervet Int Bv Vacina para o tratamento de osteoatrite em um vertebrado, uso de citocinas il-ibeta e opcionalmente inf-alfa, e, tratamento de osteoartrite em um vertebrado.
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2780130A1 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
WO2011116344A2 (en) 2010-03-18 2011-09-22 The Uab Research Foundation Targeting cancer stem cells
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2462950A1 (de) 2010-12-08 2012-06-13 Neovacs Stark inaktivierter und weiterhin hoch immunogener Impfstoff, sowie Verfahren zu seiner Herstellung
RU2013125147A (ru) 2010-12-08 2015-01-20 Неовакс Сильно инактивированная иммуногенная вакцина, сохраняющая высокую иммуногенность, и способ ее изготовления
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性Ａ−βに対する抗体を生成させるための能動免疫
CN103376327A (zh) * 2012-04-28 2013-10-30 通用电气公司 检测抗体或融合蛋白的浓度的方法
ES2912989T3 (es) 2015-05-05 2022-05-30 Rubicon Biotechnology Llc Inmunoterapia para cáncer
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE107362T1 (de) 1986-06-20 1994-07-15 Dainippon Pharmaceutical Co Polypeptid-mutanten des menschlichen tnf und für diese mutanten codierende dns.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU634379B2 (en) 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Also Published As

Publication number Publication date
TW510921B (en) 2002-11-21
CN1252809A (zh) 2000-05-10
DE69834556D1 (de) 2006-06-22
SK285639B6 (sk) 2007-05-03
WO1998046642A1 (en) 1998-10-22
CZ9903657A3 (cs) 2001-09-12
EP0975668A1 (de) 2000-02-02
IL132281A0 (en) 2001-03-19
KR20010006416A (ko) 2001-01-26
NO995002D0 (no) 1999-10-14
ES2264569T3 (es) 2007-01-01
KR100522289B1 (ko) 2005-10-19
BR9811462A (pt) 2000-09-12
CA2289476A1 (en) 1998-10-22
JP2001521386A (ja) 2001-11-06
DE69834556T2 (de) 2007-05-10
NZ337955A (en) 2000-09-29
AR012427A1 (es) 2000-10-18
HRP980203A2 (en) 1998-12-31
NO995002L (no) 1999-12-15
HUP0001930A3 (en) 2001-10-29
PL194221B1 (pl) 2007-05-31
HK1022918A1 (en) 2000-08-25
PL336295A1 (en) 2000-06-19
EP0975668B1 (de) 2006-05-17
CN1178955C (zh) 2004-12-08
SK140999A3 (en) 2000-06-12
SI0975668T1 (sl) 2007-02-28
RU2241715C2 (ru) 2004-12-10
UA72440C2 (en) 2005-03-15
HRP980203B1 (en) 2003-04-30
TR199902562T2 (xx) 2000-02-21
AU743400B2 (en) 2002-01-24
HUP0001930A2 (hu) 2000-09-28
ZA983148B (en) 1999-10-15
AU7030398A (en) 1998-11-11
US7118750B1 (en) 2006-10-10
DK0975668T3 (da) 2006-09-25
EE9900461A (et) 2000-06-15

Similar Documents

Publication Publication Date Title
ATE326481T1 (de) Veränderte tnfalpha-moleküle, dns, welche für derartige veränderte tnfalpha-moleküle kodiert und impfstoffe, die derartige veränderte tnfalpha-moleküle und dns enthalten
DE69533634D1 (de) Geranylgeranyldiphosphate-Synthase und diese kodierende DNA
DE69839406D1 (de) Modulare, platzsparende und multidirektionelle Osteosynthesevorrichtung für die Wirbelsäule
BR9704776A (pt) Dispositivo e processo de micro-reservatório de dna
BR9707438B1 (pt) esterilizador quìmico de ação rápida.
HUP0104296A3 (en) Cross-linked hyaluronic acids, uses thereof and biological substances containing them
BR9814812B1 (pt) processo de mistura e aparelhagem para realização do processo.
DK0968750T3 (da) Gas-væskekontaktapparat
DE69815529D1 (de) Acrylonitril-derivate, verfahren zu ihrer herstellung und diese enthaltende schädlingsbekämpfungsmittel
BR9506868A (pt) Recipiente para produtos químicos
EP1001964A4 (de) Tango-78, tango-79 und tango-81 nukleinsäuremoleküle und polypeptide
NO901535D0 (no) Molekylaersikter og anvendelse derav som oksydasjonskatalysator.
FI953578L (fi) Ksylanaasi, sitä tuottava mikro-organismi, DNA-molekyyli, menetelmä ksylanaasin valmistamiseksi ja sen käyttö
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
EP0749312A4 (de) DIROFILARIA IMMITIS - Gp29 - PROTEINE, NUKLEINSÄUREMOLEKÜLE UND IHRE VERWENDUNGEN
ID24173A (id) 1,2,3,4,5,6 heksahidro-2-6-metano-3-benzazosin-10-ol, proses pembuatan dan penggunannya untuk obat-obatan
DE69433915D1 (de) MDC-Proteine und dafür kodierende DNS
BR9915745B1 (pt) aparelho de moldagem compacto e processo de moldagem.
ID26243A (id) Proses penyiapan butanediol, butirolakton dan tetrahidrofuran
DE69833142D1 (de) Baugruppe mit Kontktfedern für Schalter, Verfahren und Einrichtung zur Herstellung, und diese enthaltende Schalter
IT1307027B1 (it) Utilizzo di frammenti di dna applicati localmente.
BR9506270A (pt) Receptor de elicitador de glucano e molécula de dna codificado para o mesmo
EP1058737A4 (de) Fdrg protein und nukleisäuremoleküle und ihre verwendung
TR199501521A2 (tr) Amid destekli oligoribonükleotidler.
EP1109824A4 (de) Neue 'bag'-proteine und die dafür kodierenden nukleinsäuremoleküle

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0975668

Country of ref document: EP

REN Ceased due to non-payment of the annual fee